Benitec Biopharma Inc. will provide an update on six patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 for Oculopharyngeal Muscular Dystrophy on November 3, 2025 at 8:00 am EST. The company’s proprietary “Silence and Replace” platform combines RNA interference with gene therapy to develop genetic medicines. Benitec is focused on creating therapeutics for chronic and life-threatening conditions. For more information, visit their website at www.benitec.com. Investor Relations Contact: Irina Koffler, LifeSci Advisors, Tel: (917) 734-7387, [email protected].

Read more at GlobeNewswire: Benitec Biopharma to Provide Phase 1b/2a Clinical Study